

## US Patent Office Allows Key Patent for VTI

- **USPTO allows key patent that covers design of NaturalVue Multifocal contact lenses in the US until 2036**
- **Builds on US patent granted last year that covers until 2034 the use of NaturalVue Multifocal contact lenses for treating myopia progression in children**

**Atlanta, GA, USA 22 September 2021:** Visioneering Technologies (ASX:VTI), a US-based medical device company producing NaturalVue® Contact Lenses, is pleased to announce that the US Patent and Trademark Office (USPTO) has allowed a key patent that is expected to provide coverage of VTI's unique NaturalVue Multifocal contact lens design until 2036.

The USPTO has provided a notification of allowance for a key patent titled "Induced Aperture Lens and Method" which covers design elements of VTI's NaturalVue Multifocal contact lenses until 2036. This patent has already been allowed in Australia, Singapore, and China, and remains pending in Europe. VTI expects the formal granting and issuance of a patent number by the USPTO to be completed by the end of 2021.

This recent patent allowance further demonstrates the uniqueness of VTI's optical design, and expands VTI's patent estate covering the design and use of its NaturalVue Multifocal contact lenses. These lenses have a unique design that has been shown to assist patients with presbyopia (age-related loss of near vision) and significantly slow the progression of myopia (short-sightedness) in children.

Due to the rapidly increasing prevalence of myopia around the world, and the serious lifetime risks associated with myopia, slowing the year-over-year worsening of myopia early in life has become a rapidly growing area of new product development and commercial interest for the multinational eye care companies and a number of new emerging companies. In real-world clinical settings NaturalVue Multifocal contact lenses have been shown to slow the progression of myopia in children, while providing excellent vision. Last year, VTI announced the granting of another key patent that protects its designs when used for treating myopia progression in children. This patent was also issued in the key markets of China, Singapore, and Australia.

Stephen Snowdy, PhD, VTI's Chief Executive Officer commented, "With this new patent, VTI has added substantially to the long-term protection of its existing commercial products and to the value of its intellectual property portfolio. This achievement intersects with rapidly increasing interest in the management of myopia large eye care companies entering the space."

**Ends**

This release was authorized by the CEO, Stephen Snowdy, PhD.

For more information, please contact:

### Visioneering Technologies

**Stephen Snowdy, PhD**

CEO

E: [ssnowdy@vtivision.com](mailto:ssnowdy@vtivision.com)

### About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

### Foreign ownership restrictions

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation,

For personal use only

U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only